« Return to News | R&D Trends

Children benefit from nearly 300 meds in development

Friday, January 13, 2012 01:42 PM

Today, a whopping 282 medicines to treat children and adolescents are in clinical trials or under review by the FDA, according to a report by Pharmaceutical Research and Manufacturers of America (PhRMA).

Medicine has been key in recent decades in fighting diseases that impact children. New vaccines, antibiotics, and major treatments protect children against many childhood and infections diseases, as well as cancer. With 30 years of advancement, the percentage of children with cancer surviving for five years of longer has increased by 24 percentage points.

Of the nearly 300 medicines in the report, 54 are for cancer, 49 for infectious diseases, 48 for genetic disorders and 25 for neurologic disorders. In addition to developing new medicines, researches are testing existing medicines to determine safe and effective dosage levels for children.

Biopharmaceutical research companies are working to continue this progress, which has plunged infant mortality to record lows, but the termination of the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) in October 2012, unless reauthorized or made permanent by Congress, will cease many research possibilities.

“Reauthorization of these pivotal programs is essential to continued progress in children’s health,” said John J. Castellani, president and CEO of PhRMA. “Permanent reauthorization would provide much-needed predictability and certainty, to the benefit of regulators, innovative companies and, ultimately, children.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.